What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.
Fate Shares Dip Below Their IPO Price
Nov 6, 2013
(FATE) shares slipped below their October 1st $6 IPO price for the first time, despite the recent high-profile publication
of encouraging results from its Phase 1 ProHema trial and apparent progress in Phase 2 trials. FATE closed the day at $5.95.
Fate Therapeutics IPO Comes In at Bottom of Price Range
Oct 2, 2013
(FATE) final prospectus
for its IPO, filed yesterday with the SEC, prices the offering of 7.7 million shares at $6 per share, the bottom of its previously anticipated range ($6-$8). Fate now becomes the 17th publicly traded U.S. stem cell-focused company to be covered by the SCSI.
Fate Therapeutics Prices IPO
Oct 1, 2013
, developer of stem cell modulating drugs, priced
its IPO yesterday at $6-$8 per share for up to 7.7 million shares. At the midpoint of that range, the company's market cap would be $64 million. The proceeds will advance the company's current Phase 2 trial of ProHema (a hematopoietic stem cell modulator) as well as its preclinical Wnt7a program. At the offer's closing, Fate will become the SCSI's 17th component company.
Fate Therapeutics IPO Moving Forward
Sep 18, 2013
San Diego-based Fate Therapeutics
, developer of stem cell-modulating drugs, took another step toward its IPO yesterday by filing an SEC form 8-A
registration. The company intends to offer 4 million shares at $14-$16 per share. Upon completion of this initial public offering Fate will become the 17th SCSI component company, and its 3 current clinical trials will join our Clinical Trials Monitor
. Its shares will trade on the NASDAQ market under the symbol "FATE".
Fate Therapeutics Plans IPO
Aug 15, 2013
Fate Therapeutics< Previous Page
filed an S-1
with the SEC yesterday, signaling its intention to pursue a $69M IPO. If successful, the stem cell modulator company would become the third new component company added to our Stem Cell Stock Index this year. Its ProHema product (currently in a Phase 2 trial for marrow reconstitution) might compete with Cytomedix
's (CMXI) Aldagen products.
| Next Page >